Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cassava Sciences Enters Drug Supply Agreement with Evonik | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Cassava Sciences Enters Drug Supply Agreement with Evonik

Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Cassava Sciences Inc., a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease.
 
“I am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains,” said Remi Barbier, president and CEO of Cassava Sciences.
 
“We are delighted to be collaborating with Cassava and contributing to fight Alzheimer’s together. We are committed to supporting Cassava in their goals to maintain the quality of life for millions of patients around the world and to further advance potential treatment options,” commented Dr. Thomas Riermeier, head of Evonik’s Health Care business line.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters